Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial

Sander Klis1, Adelita Ranchor2, Richard O. Phillips3, Kabiru M. Abass4, Wilson Tuah5, Susanne Loth1, Kristien Velding1, Tjip S. van der Werf1,6, Ymkje Stienstra1

1 Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, the Netherlands, 2 Department of Health Sciences, Section Health Psychology, University Medical Center Groningen, Groningen University, Groningen, the Netherlands, 3 Department of Internal Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana, 4 Agogo Presbyterian Hospital, Agogo, Ghana, 5 Nkawie-Toase Government Hospital, Nkawie, Ghana, 6 Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, the Netherlands

Abstract

Background: Buruli Ulcer is a tropical skin disease caused by Mycobacterium ulcerans, which, due to scarring and contractures can lead to stigma and functional limitations. However, recent advances in treatment, combined with increased public health efforts have the potential to significantly improve disease outcome.

Objectives: To study the Quality of Life (QoL) of former Buruli Ulcer patients who, in the context of a randomized controlled trial, reported early with small lesions (cross-sectional diameter <10 cm), and received a full course of antibiotic treatment.

Methods: 127 Participants of the BURULICO drug trial in Ghana were revisited. All former patients aged 16 or older completed the Dermatology Life Quality Index (DLQI) and the abbreviated World Health Organization Quality of Life scale (WHOQOL-BREF). The WHOQOL-BREF was also administered to 82 matched healthy controls. Those younger than 16 completed the Childrens’ Dermatology Life Quality Index (CDLQI) only.

Results: The median (Inter Quartile Range) score on the DLQI was 0 (0–4), indicating good QoL. 85% of former patients indicated no effect, or only a small effect of the disease on their current life. Former patients also indicated good QoL on the physical and psychological domains of the WHOQOL-BREF, and scored significantly higher than healthy controls on these domains. There was a weak correlation between the DLQI and scar size (r = 0.32; p < 0.001).

Conclusions: BU patients who report early with small lesions and receive 8 weeks of antimicrobial therapy have a good QoL at long-term follow-up. These findings contrast with the debilitating sequelae often reported in BU, and highlight the importance of early case detection.

Introduction

Buruli ulcer (BU) is listed by the World Health Organization (WHO) as a neglected tropical disease, caused by infection with Mycobacterium ulcerans. Although the disease has been reported from as many as 30 countries around the world, it is currently most common in West and Central Africa, and it predominantly affects the rural poor. Typically, the disease starts with a small, painless nodule that progresses into a large necrotizing ulcer over the course of several weeks. After treatment, although the ulcer usually heals, there is a high risk of significant scarring, contractures and functional limitations [1–3].

In the socio-economic context of rural Africa, functional limitations and stigmatizing scars can have severe consequences. In a study of 638 former BU patients in Ghana and Benin, 57% appeared to have a functional limitation, and school dropout, financial difficulties and job loss were frequent consequences of the disease [2]. People in endemic communities sometimes perceive the disease to be caused by a curse or witchcraft, and the resulting stigma can cause social isolation and problems with finding work
or a spouse [4–6]. Although the treatment for BU is free of charge, the costs associated with hospitalization can be devastating for the household economy and frequently cause family members to cease providing financial and social support to patients [7].

However, over the past decade, the main mode of treatment has shifted from surgery to antibiotics, with high rates of cure [8]. In addition, significant public health efforts have been directed at detecting BU at an early stage and educating affected communities about the disease. Conceptually, both factors combined should reduce scarring, contractures, and stigma, and improve the subsequent quality of life (QoL) of former patients.

To our knowledge, the QoL of former BU patients has not yet been studied. In leprosy and poxmodisisis, similarly deforming and stigmatizing skin conditions occurring in the tropics, several studies on QoL have been conducted in Bangladesh, Brazil, China, Ethiopia, Ghana, and India [9–15]. In general, these studies show that patients report a substantially lower QoL than controls [9–11]. There appears to be some relationship between QoL and the severity of the disease in terms of number of lesions, functional limitations, stigma, and deformities [11–15]. Studies from Ethiopia in poxmodisisis patients, a disabling and stigmatizing geochemical elephantiasis of the foot, found that a dermatology-specific QoL instrument was valid and sensitive to therapeutic change [16,17].

These studies demonstrate that measuring QoL with standardized questionnaires in rural Africans suffering from skin diseases is feasible. Moreover, as both leprosy and poxmodisisis were shown to have a significant impact on QoL, they show that measuring QoL in these populations is warranted. In the current study, we report on the disease-specific and general QoL of former BU patients who previously presented with small, early ulcers and who were treated with a full course of 8 weeks of antibiotics.

Methods
Sample size and patient recruitment
Our study subjects were former BU patients that had earlier participated in the BURULICO trial, conducted between 2006 and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients who previously presented with small, early ulcers and who report on the disease-specific and general QoL of former Buruli ulcer patients. In the current study, we assessed the quality of life of healed Buruli ulcer patients that took part in a drug trial between 2006 and 2009, which only included small and early lesions. On follow-up, we found that most scars were small and functional limitations were rare, and that both general and skin specific Quality of Life was good. Our results demonstrate the potential of the combination of early detection and proper antibiotic treatment of Buruli ulcer and hence stress the importance of public health efforts aimed at diagnosing the disease in its early stage, and providing standardized treatment in endemic areas.
that the back translations were not reviewed by the authors of the questionnaire but by the study team. Effect sizes of the difference in WHOQOL-BREF domains between former patients and controls were calculated using the formula $z/N$, where $z$ is the $z$-score of the U statistic, and $N$ is the total sample size.

The Buruli Ulcer Functional Limitation Score (BUFLS) is a questionnaire that consists of questions related to 19 common daily activities of people living in endemic areas [2,23]. Each item is scored between 0 and 2, with 0 indicating no difficulties in performing the activity compared to age- and sex matched community members, 1 indicating difficulties performing the activity, and 2 indicating that the former patient is unable to carry out the activity at all. In the calculation of the individual functional limitation score, the sum is divided by the maximum possible score for that individual, multiplied by 100%. A higher score therefore indicates more functional limitations, with a range between 0% and 100%. A score cannot be calculated if more than 6 items are not applicable.

### Procedures

Former patients currently aged 16 or above were administered the WHOQOL-BREF, DLQI and BUFLS questionnaires, and former patients currently aged below 16 were administered the CDLQI and BUFLS only. The WHOQOL-BREF was also administered to 82 age, sex, and occupation (farming, schooling or other) matched healthy controls that lived in the same villages as the former BU patients on separate visits. All potential controls were asked whether they were on any medication; they could only participate if they answered both questions with no. Due to high rates of illiteracy among the participants, all questionnaires were administered orally in a quiet private place by three trained local hospital staff members. In addition all patients were asked about the presence of pain (Yes/No) and itch (Yes/No), marital status, level of education and employment. Also, for all former patients the scar size was determined by tracing it on a transparent sheet, scanning it, and measuring the surface with ImageJ software.

### Ethics

The study protocol was approved by the Committee on Human Research, Publication, and Ethics of the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital, Kumasi (reference number CHRPE/AP/133/12). Written and verbal informed consent or assent was obtained from all participants aged ≥12 years, and consent from parents, or legal representatives of participants aged ≤18 years.

### Results

#### Patient population

127 individuals (84%) of the 151 former participants of the BURULICO trial were located for follow up, and none declined to participate. The median duration between drug treatment and enrolment in the current study was 5 years. Although the trial had taken place in the Ashanti region of Ghana, many former patients had moved away from the study site, and patients were retrieved in 9 of 10 Ghanaian regions, including the three Northern regions more than 700 kilometers and approximately 10 hours by road from the original study site. 68% of the retrieved former patients were female, and the median age at follow-up was 18 years. 71 former patients were age-eligible, and completed the DLQI, but due to an error the WHOQOL-BREF was not administered to 4 former patients, so data on this questionnaire were only available for 67 former patients. The remaining 56 former patients were administered the CDLQI only. There was no missing data on the DLQI and CDLQI, and a maximum of 2 missing answers per QoL domain on the WHOQOL-BREF, meaning that domain scores could be calculated for every subject. Item 21 of the WHOQOL-BREF, “how satisfied are you with your sex life?”, caused considerable confusion among many former patients who were not married. Even after repeated explanation that one could still have an opinion about one’s sex life if you are not married (i.e. be dissatisfied with it), it was poorly understood and hence left open on 20 of the 67 questionnaires. Due to a printing error, the BUFLS was not administered to one former patient, but meaningful scores (i.e. less than 6 items not applicable) could be computed for all other patients.

Of the 24 former patients not retrieved, 4 were already lost to follow-up during the BURULICO trial, 3 had moved abroad, 2 had deceased, and the fate of the remaining 15 was unknown. The former patients that were lost to follow-up did not differ significantly from those that were retrieved in terms of age, gender or treatment arm.

#### Quality of Life scores and patient characteristics

Scores, range, and reliability for the DLQI, CDLQI, and WHOQOL-BREF subscales are shown in Table 1. The frequency distributions of the QoL scales are shown in Figure 1. Upon inspection, it appears that the psychological and environmental subscales of the WHOQOL-BREF were normally distributed. The distribution of the DLQI and CDLQI is skewed to the left. The banding scores for the DLQI and CDLQI are shown in Figure 2.

### Table 1. Scale descriptives for the DLQI, CDLQI and WHOQOL-BREF subscales.

<table>
<thead>
<tr>
<th>Scale</th>
<th>Mean (SD)</th>
<th>Median (IQR)</th>
<th>Range</th>
<th>Cronbach’s α</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLQI</td>
<td>2.3 (3.4)</td>
<td>0 (0–4)</td>
<td>0–11</td>
<td>.78</td>
</tr>
<tr>
<td>CDLQI</td>
<td>2.6 (3.2)</td>
<td>1 (0–4.5)</td>
<td>0–11</td>
<td>.57</td>
</tr>
<tr>
<td>WHOQOL-BREF Physical</td>
<td>75.9 (12.0)</td>
<td>80 (69–86)</td>
<td>37–94</td>
<td>.63</td>
</tr>
<tr>
<td>WHOQOL-BREF Psychological</td>
<td>70.9 (12.1)</td>
<td>70 (60–80)</td>
<td>40–97</td>
<td>.62</td>
</tr>
<tr>
<td>WHOQOL-BREF Social</td>
<td>67.9 (18.0)</td>
<td>68 (53–80)</td>
<td>20–100</td>
<td>.55</td>
</tr>
<tr>
<td>WHOQOL-BREF Environmental</td>
<td>65.1 (11.6)</td>
<td>68 (58–73)</td>
<td>35–88</td>
<td>.66</td>
</tr>
</tbody>
</table>

N = 71 for the DLQI, N = 67 for the WHOQOL-BREF, and N = 56 for the CDLQI. SD = standard deviation, IQR = interquartile range. DLQI = Dermatology Life Quality Index, CDLQI = Children’s Dermatology Life Quality Index, WHOQOL-BREF = abbreviated World Health Organisation Quality of Life instrument. doi:10.1371/journal.pntd.0002964.t001
Former patients had a median (IQR) scar size of 4.6 (1.4–13.5) cm², and a median (IQR) BUFLS score of 2.6% (0%–13.3%). Only 4 (3%) former patients were unemployed, all others were either studying or working. Only 52% of former patients were married, but those not married were significantly younger ($t = 2.31; p = 0.024$). The scar was itchy in 26% and painful in 9% of former patients.

**Associations between Quality of Life instruments and patient characteristics**

Spearman’s Rho correlations between the DLQI, CDLQI and WHOQOL-BREF subscales and other continuous variables are shown in Table 3. Age was not significantly related to any of the QoL scales. Scar size correlated significantly with the DLQI.
Quality of Life in Former Buruli Ulcer Patients with Small Lesions

Table 2. Banding scores of the DLQI and CDLQI.

<table>
<thead>
<tr>
<th>Effect of scar or contracture on patients’ life</th>
<th>DLQI (N = 67)</th>
<th>CDLQI (N = 56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No effect</td>
<td>63%</td>
<td>54%</td>
</tr>
<tr>
<td>Small effect</td>
<td>22%</td>
<td>32%</td>
</tr>
<tr>
<td>Moderate effect</td>
<td>10%</td>
<td>14%</td>
</tr>
<tr>
<td>Very large effect</td>
<td>5%</td>
<td>0%</td>
</tr>
<tr>
<td>Extremely large effect</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

DLQI = Dermatology Life Quality Index, CDLQI = Children’s Dermatology Life Quality Index.

The DLQI correlated significantly with the environmental subscale of the WHOQOL-BREF \((p = 0.29; p < 0.01)\). The BUFLS correlated significantly with the environmental subscale of the WHOQOL-BREF \((p = -0.24; p < 0.05)\). Relationships between the QoL instruments and discrete variables were tested through either student T-tests or Mann-Whitney U tests depending on whether the scales were normally distributed. The QoL of women did not differ from men on any of the scales or subscales. Farmers, scored significantly higher on the social domain of QoL compared to other professions \((U = 435; p = 0.050)\). Those who were married also scored significantly higher on the social domain than those who were single \((U = 375; p = 0.019)\). Those who were ethnically Akan scored significantly higher on the DLQI \((U = 332; p = 0.026)\), indicating lower QoL, and significantly lower on the physical domain of QoL \((U = 292; p = 0.003)\), again indicating lower QoL than those from the northern tribes. None of the QoL scores differed between those that did or did not report painful or itchy scars.

The DLQI correlated significantly with the physical \((p = -0.54; p < 0.001)\) and psychological \((p = -0.34; p < 0.001)\) subscales of the WHOQOL-BREF, but did not correlate at all with the social \((p = 0.00; p = 0.99)\) and environmental \((p = -0.01; p = 0.98)\) subscales.

Quality of life of former BU patients compared to healthy controls

Scores on the WHOQOL-BREF domains of patients and healthy controls are shown in Figure 2. Former BU patients scored significantly higher than controls on the physical and environmental domains of the WHOQOL-BREF by Mann-Whitney U tests. The effect sizes for the four domains were as follows: physical 0.29, environmental 0.41, psychological 0.10, and social 0.14.

Discussion

This is the first study to address QoL in former BU patients. The former BU patients with small lesions that we studied appeared to have a good QoL. When measured with the DLQI, a disease specific questionnaire, 85% of patients indicated no or a small effect of the disease on their current life. The median score found was 0 compared to 13 in active and 3 in healed podoconiosis patients in Ethiopia [16], and median scores between 2 and 12 in patients with various active skin diseases in South Africa [21]. In the current study, scores on a measure of general QoL were high, especially in the physical domain of QoL, but – likely owing to the poor rural setting – lower on the environmental domain, which relates to issues such as access to healthcare and transportation, and financial resources. In addition, former patients indicated an equal or better QoL compared to healthy controls in all four domains measured.

As their scars and functional limitations were limited, it could be expected that former patients would not differ much from controls in QoL. However, it is surprising that they would report a higher physical and environmental QoL, with small to medium effect sizes. As controls were matched to former patients on age, gender, village and occupation, it is difficult to explain these findings on the basis of social or economic factors. Perhaps having been confronted with BU and the prospect of scarring and disability, made patients adjust their internal standards of what constitutes good physical functioning. This, in turn, would cause them to appreciate the preserved physical functioning they have today, a phenomenon known as response shift [24]. One possible explanation for indicating a better environmental QoL could be their positive experience with the healthcare system for the treatment of their BU, which is free of charge and relatively well-organized in the study regions. However, it is also possible that the interviewers were viewed by former patients as representatives of the hospitals where they were treated, causing them to answer in a more socially desirable way than controls. Another possible explanation is that we followed-up a group who presented early, in contrast with most BU patients, and that this was a consequence of this group having more access to healthcare and other resources, i.e. through being more educated or living less isolated.

Table 3. Spearman’s Rho correlations between QoL scales and other continuous variables.

<table>
<thead>
<tr>
<th></th>
<th>BUFLS</th>
<th>CDLQI</th>
<th>WHOQOL-BREF Phys</th>
<th>WHOQOL-BREF Psy</th>
<th>WHOQOL-BREF Soc</th>
<th>WHOQOL-BREF Env</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scar size</td>
<td>0.52*</td>
<td>0.12</td>
<td>−0.14</td>
<td>−0.20</td>
<td>−0.06</td>
<td>−0.08</td>
</tr>
<tr>
<td>Age</td>
<td>−0.01</td>
<td>−0.01</td>
<td>0.16</td>
<td>0.30</td>
<td>0.19</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* = p < 0.05, ** = p < 0.01.

DLQI = Dermatology Life Quality Index, CDLQI = Children’s Dermatology Life Quality Index, WHOQOL-BREF = abbreviated World Health Organisation Quality of Life Instrument, BUFLS = Buruli ulcer Functional Limitation Score.

doi:10.1371/journal.pntd.0002964.t003
and hence a better baseline QoL than the average community member.

The good QoL of former patients with small lesions found in this study corresponded with the more physical measures of BU sequelae. Patients had a relatively small median scar size. In addition their level of functional limitations as measured by the BUFLS was low, with a median score of 2.6%, compared to earlier scores of 5.3% in a large cohort of BU patients with varying lesion sizes that was treated outside of any study context [2], and 16% in patients who had only received surgical or traditional treatment [25].

The DLQI had a Cronbach’s alpha of 0.78 indicating satisfactory internal consistency [26]. In addition, it was significantly related to scar size, which can be seen as a proxy measure of disease severity, and to both the psychological and physical QoL domains of the WHOQOL-BREF in the expected directions. Similar to two previous studies with the DLQI in Sub-Saharan Africa, we did not find DLQI scores to be related to gender [16,21]. Together, these findings suggest that the DLQI is a valid instrument for measuring disease-specific QoL in BU patients aged 16 and above, although further research in larger samples, including larger lesions is needed. In children, the CDLQI had a low Cronbach’s alpha, and was not related to any of the background variables, which makes it difficult to ascertain its validity. The Cronbach’s alphas for the WHOQOL-BREF subscales were below 0.7, indicating questionable internal consistency. The social domain of QoL was related to being married and working as a farmer, and the physical and psychological domains were related to disease specific QoL in the expected directions. Former patients indicated a higher QoL on all 4 domains of the WHOQOL-BREF than controls, which is rather unexpected. In addition, item 21, satisfaction with one’s sex life, was poorly understood by those who were not married, and was left open by a considerable proportion/number of former patients. Overall, these data do not clearly establish the validity of the WHOQOL-BREF for measuring general QoL in former BU patients.

The present study suffered from several limitations. First the sample size was relatively small, with only 67 adults completing both adult QoL instruments. As the cohort under study was predetermined by the BURULICO trial, we were not able to increase the sample size. This could have left the study underpowered to pick up associations between the questionnaires and background variables such as gender. However, several significant associations were indeed found. In addition, we were not able to recruit healthy controls for the DLQI and CDLQI as these are disease specific questionnaires, and thus had to rely on the earlier proposed norm scores, but the very low scores on both instruments are likely to reflect good QoL. Finally, we did not study QoL in former BU patients that were treated under normal service conditions. These patients would have likely had larger lesions and might have reported a lower QoL, and data on these patients could have helped to establish the validity of the questionnaires, although in our sample the DLQI already correlated significantly with scar size.

In this study, we show that in BU patients who reported early with small lesions and received either 8 weeks of streptomycin and rifampicin or 4 weeks of streptomycin and rifampicin followed by 4 weeks of clarithromycin and rifampicin, scars were small, functional limitations were uncommon and long term QoL was preserved. These findings contrast the debilitating sequelae often reported in BU, highlighting the importance of active case finding and antimicrobial treatment of BU lesions. The Twii version of the DLQI appeared to be a valid instrument to measure disease specific QoL in BU patients aged 16 or older, and was quick and easy to administer under field conditions. For children, the Twii version of the CDLQI appeared to be a less valid instrument in this population, though alternatives are lacking. The validity of the WHOQOL-BREF for measuring general QoL in former BU patients is questionable. Future studies on QoL in BU should attempt to include patients with active BU, and should include patients with larger lesions. In addition they should include alternative questionnaires for measuring general QoL in BU, such as the SF-36, or limit themselves to disease-specific QoL using the DLQI.

Supporting Information

Checklist S1  STROBE checklist. (DOC)

Acknowledgments

We would like to thank Professor Andrew Y Finlay and Dr Mohammad K. A. Barra, Department of Dermatology, Cardiff University School of Medicine, for providing us with the DLQI, and CDLQI to use in this study, and for their help with translating the questionnaire into Twii.

Author Contributions

Conceived and designed the experiments: SK TSvW YS AR. Performed the experiments: SK SL KMA WT. Analyzed the data: SK SL KV. Contributed to the writing of the manuscript: SK KV TSvW ROP YS AR.

References


